Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model

Yoji Nagasaki, Yoshihiro Eriguchi, Yujiro Uchida, Noriko Miyake, Yoriko Maehara, Masako Kadowaki, Mine Harada, Koichi Akashi, Nobuyuki Shimono

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: Antifungal monotherapy with polyenes, azoles or echinocandins is not always effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to evaluate the efficacy of a combination of micafungin and amphotericin B for the primary treatment of IPA in an immunocompromised mouse model. Methods: Female ICR mice were used in all experiments. An immunosuppressive state was induced in mice by an intraperitoneal injection of cyclophosphamide. Mice were intratracheally inoculated with Aspergillus fumigatus conidia, treated with micafungin, amphotericin B or both for 7 days, and were tested for their survival 20 days after the Aspergillus inoculation. Fungal burden in lungs, serum galactomannan index (GMI) and histopathology of lungs, spleen and kidneys were also evaluated. Results: Combination therapy with micafungin and amphotericin B gave excellent survival of infected mice compared with monotherapy with micafungin or amphotericin B alone. Combined therapy reduced the fungal burden in the lungs and the serum GM levels compared with monotherapy or untreated controls, resulting in a significant histological improvement with disappearance of fungi in the lungs. Conclusions: These findings suggest that combination therapy with micafungin and amphotericin B is more effective compared with monotherapy with either of them alone for IPA treatment.

Original languageEnglish
Pages (from-to)379-382
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume64
Issue number2
DOIs
Publication statusPublished - Jul 24 2009

Fingerprint

Invasive Pulmonary Aspergillosis
Amphotericin B
Lung
Echinocandins
Polyenes
Therapeutics
Azoles
Inbred ICR Mouse
Aspergillus fumigatus
Fungal Spores
Aspergillus
Immunosuppressive Agents
Intraperitoneal Injections
Serum
Cyclophosphamide
Fungi
Spleen
micafungin
Kidney

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. / Nagasaki, Yoji; Eriguchi, Yoshihiro; Uchida, Yujiro; Miyake, Noriko; Maehara, Yoriko; Kadowaki, Masako; Harada, Mine; Akashi, Koichi; Shimono, Nobuyuki.

In: Journal of Antimicrobial Chemotherapy, Vol. 64, No. 2, 24.07.2009, p. 379-382.

Research output: Contribution to journalArticle

@article{576b795d04e04b299b95b47d0e4fc2ed,
title = "Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model",
abstract = "Objectives: Antifungal monotherapy with polyenes, azoles or echinocandins is not always effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to evaluate the efficacy of a combination of micafungin and amphotericin B for the primary treatment of IPA in an immunocompromised mouse model. Methods: Female ICR mice were used in all experiments. An immunosuppressive state was induced in mice by an intraperitoneal injection of cyclophosphamide. Mice were intratracheally inoculated with Aspergillus fumigatus conidia, treated with micafungin, amphotericin B or both for 7 days, and were tested for their survival 20 days after the Aspergillus inoculation. Fungal burden in lungs, serum galactomannan index (GMI) and histopathology of lungs, spleen and kidneys were also evaluated. Results: Combination therapy with micafungin and amphotericin B gave excellent survival of infected mice compared with monotherapy with micafungin or amphotericin B alone. Combined therapy reduced the fungal burden in the lungs and the serum GM levels compared with monotherapy or untreated controls, resulting in a significant histological improvement with disappearance of fungi in the lungs. Conclusions: These findings suggest that combination therapy with micafungin and amphotericin B is more effective compared with monotherapy with either of them alone for IPA treatment.",
author = "Yoji Nagasaki and Yoshihiro Eriguchi and Yujiro Uchida and Noriko Miyake and Yoriko Maehara and Masako Kadowaki and Mine Harada and Koichi Akashi and Nobuyuki Shimono",
year = "2009",
month = "7",
day = "24",
doi = "10.1093/jac/dkp175",
language = "English",
volume = "64",
pages = "379--382",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model

AU - Nagasaki, Yoji

AU - Eriguchi, Yoshihiro

AU - Uchida, Yujiro

AU - Miyake, Noriko

AU - Maehara, Yoriko

AU - Kadowaki, Masako

AU - Harada, Mine

AU - Akashi, Koichi

AU - Shimono, Nobuyuki

PY - 2009/7/24

Y1 - 2009/7/24

N2 - Objectives: Antifungal monotherapy with polyenes, azoles or echinocandins is not always effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to evaluate the efficacy of a combination of micafungin and amphotericin B for the primary treatment of IPA in an immunocompromised mouse model. Methods: Female ICR mice were used in all experiments. An immunosuppressive state was induced in mice by an intraperitoneal injection of cyclophosphamide. Mice were intratracheally inoculated with Aspergillus fumigatus conidia, treated with micafungin, amphotericin B or both for 7 days, and were tested for their survival 20 days after the Aspergillus inoculation. Fungal burden in lungs, serum galactomannan index (GMI) and histopathology of lungs, spleen and kidneys were also evaluated. Results: Combination therapy with micafungin and amphotericin B gave excellent survival of infected mice compared with monotherapy with micafungin or amphotericin B alone. Combined therapy reduced the fungal burden in the lungs and the serum GM levels compared with monotherapy or untreated controls, resulting in a significant histological improvement with disappearance of fungi in the lungs. Conclusions: These findings suggest that combination therapy with micafungin and amphotericin B is more effective compared with monotherapy with either of them alone for IPA treatment.

AB - Objectives: Antifungal monotherapy with polyenes, azoles or echinocandins is not always effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to evaluate the efficacy of a combination of micafungin and amphotericin B for the primary treatment of IPA in an immunocompromised mouse model. Methods: Female ICR mice were used in all experiments. An immunosuppressive state was induced in mice by an intraperitoneal injection of cyclophosphamide. Mice were intratracheally inoculated with Aspergillus fumigatus conidia, treated with micafungin, amphotericin B or both for 7 days, and were tested for their survival 20 days after the Aspergillus inoculation. Fungal burden in lungs, serum galactomannan index (GMI) and histopathology of lungs, spleen and kidneys were also evaluated. Results: Combination therapy with micafungin and amphotericin B gave excellent survival of infected mice compared with monotherapy with micafungin or amphotericin B alone. Combined therapy reduced the fungal burden in the lungs and the serum GM levels compared with monotherapy or untreated controls, resulting in a significant histological improvement with disappearance of fungi in the lungs. Conclusions: These findings suggest that combination therapy with micafungin and amphotericin B is more effective compared with monotherapy with either of them alone for IPA treatment.

UR - http://www.scopus.com/inward/record.url?scp=67650739469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650739469&partnerID=8YFLogxK

U2 - 10.1093/jac/dkp175

DO - 10.1093/jac/dkp175

M3 - Article

C2 - 19465436

AN - SCOPUS:67650739469

VL - 64

SP - 379

EP - 382

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -